Henshaw Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Henshaw Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,430	Closed	-$737K	–	257
2025 Q3	$737K	Sell	15,430 -5,624	-27%	-$226K	0.03%	134
2025 Q2	$664K	Hold	21,054	–	–	0.03%	202
2025 Q1	$690K	Buy	21,054 +1,413	+7%	+$50.1K	0.03%	182
2024 Q4	$710K	Buy	19,641 +1,740	+10%	+$61.3K	0.03%	161
2024 Q3	$558K	Hold	17,901	–	–	0.02%	208
2024 Q2	$479K	Buy	17,901 +462	+3%	+$13.4K	0.02%	180
2024 Q1	$595K	Hold	17,439	–	–	0.03%	153
2023 Q4	$505K	Hold	17,439	–	–	0.03%	171
2023 Q3	$481K	Buy	17,439 +7,254	+71%	+$221K	0.03%	160
2023 Q2	$306K	Hold	10,185	–	–	0.02%	180
2023 Q1	$369K	Hold	10,185	–	–	0.02%	156
2022 Q4	$363K	Hold	10,185	–	–	0.02%	148
2022 Q3	$345K	Buy	10,185 +1,264	+14%	+$41.1K	0.03%	185
2022 Q2	$258K	Hold	8,921	–	–	0.02%	248
2022 Q1	$288K	Hold	8,921	–	–	0.02%	255
2021 Q4	$260K	Hold	8,921	–	–	0.01%	289
2021 Q3	$238K	Hold	8,921	–	–	0.01%	297
2021 Q2	$275K	Hold	8,921	–	–	0.02%	295
2021 Q1	$234K	Hold	8,921	–	–	0.02%	316
2020 Q4	$224K	Buy	+8,921	New	+$192K	0.02%	313

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Henshaw Capital's SUPN Position: Q4 2025 in Review

Henshaw Capital sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 15,430 shares — an estimated $737K sold.

Henshaw Capital first reported a position in SUPN in Q4 2020 and held it in 20 quarters. The position peaked at $737K in Q3 2025. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

Henshaw Capital reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Henshaw Capital sold 15,430 Supernus Pharmaceuticals shares in Q4 2025, an estimated $737K.
Henshaw Capital first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 20 quarters.
Henshaw Capital's Supernus Pharmaceuticals position peaked at $737K in Q3 2025.
333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Henshaw Capital's 13F filing for Q4 2025, filed 28 May 2026.